Daniel J Kirby
Overview
Explore the profile of Daniel J Kirby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Curti C, Kirby D, Russell C
Int J Pharm
. 2024 Feb;
653:123862.
PMID: 38307399
Pharmaceutical three-dimensional printing (3DP) is now in its golden age. Recent years have seen a dramatic increase in the research in 3D printed pharmaceuticals due to their potential to deliver...
2.
Khan D, Badhan R, Kirby D, Bryson S, Shah M, Mohammed A
Pharmaceutics
. 2023 Feb;
15(2).
PMID: 36839878
The rapid onset of action of nifedipine causes a precipitous reduction in blood pressure leading to adverse effects associated with reflex sympathetic nervous system (SNS) activation, including tachycardia and worsening...
3.
Curti C, Kirby D, Russell C
Pharmaceutics
. 2021 Apr;
13(5).
PMID: 33922928
Pharmaceutical applications of 3D printing technologies are growing rapidly. Among these, vat photopolymerisation (VP) techniques, including Stereolithography (SLA) hold much promise for their potential to deliver personalised medicines on-demand. SLA...
4.
Dahmash D, Shariff Z, Kirby D, Terry D, Huynh C
BMJ Paediatr Open
. 2020 Dec;
4(1):e000841.
PMID: 33305018
Objective: To identify studies that highlighted medication administration problems experienced by parents and children, which also looked at health literacy aspect using a validated tool to assess for literacy. Study...
5.
Shariff Z, Dahmash D, Kirby D, Missaghi S, Rajabi-Siahboomi A, Maidment I
J Am Med Dir Assoc
. 2020 Apr;
21(8):1015-1023.e8.
PMID: 32224260
Objectives: Age-related changes mean that the older population can encounter barriers toward taking medication orally. Further work is needed to identify the characteristics of oral solid dosage forms that will...
6.
Joshi S, Chaudhari A, Dennis V, Kirby D, Perrie Y, Singh S
Bioengineering (Basel)
. 2018 May;
5(2).
PMID: 29747393
Although respiratory syncytial virus (RSV) is one of the leading causes of acute respiratory tract infection in infants and adults, effective treatment options remain limited. To circumvent this issue, there...
7.
Miriyala N, Ouyang D, Perrie Y, Lowry D, Kirby D
Eur J Pharm Biopharm
. 2017 Mar;
115:197-205.
PMID: 28284728
Recent research on porous silica materials as drug carriers for amorphous and controlled drug delivery has shown promising results. However, due to contradictory literature reports on toxicity and high costs...
8.
Joshi S, Hussain M, Roces C, Anderluzzi G, Kastner E, Salmaso S, et al.
Int J Pharm
. 2016 Nov;
514(1):160-168.
PMID: 27863660
Despite the substantial body of research investigating the use of liposomes, niosomes and other bilayer vesicles for drug delivery, the translation of these systems into licensed products remains limited. Indeed,...
9.
Perrie Y, Ali H, Kirby D, Mohammed A, McNeil S, Vangala A
Methods Mol Biol
. 2016 Nov;
1522:131-143.
PMID: 27837536
The structural characteristics of liposomes have been widely investigated and there is certainly a strong understanding of their morphological characteristics. Imaging of these systems, using techniques such as freeze-fracturing methods,...
10.
Kirby D, Kaur R, Agger E, Andersen P, Bramwell V, Perrie Y
Curr Drug Deliv
. 2013 Feb;
10(3):268-78.
PMID: 23410072
This present study compares the efficacy of microsphere formulations, and their method of antigen presentation, for the delivery of the TB sub-unit vaccine antigen, Ag85B-ESAT-6. Microspheres based on poly(lactide-coglycolide) (PLGA)...